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Abstract
Background: Cutaneous squamous cell carcinoma of the nasal planum in cats is a common indication for
antitumor treatment such as external beam radiation therapy. Curative-intent radiation therapy has been described
as a valuable treatment option, resulting in long and stable tumor control in these patients. The aim of the current
study was to evaluate outcome and toxicity, as well as possible prognostic factors using an accelerated
hypofractionated radiation therapy protocol.
Cats with squamous cell carcinoma of the nasal planum treated with an accelerated radiation protocol (10 × 4.8 Gy,
over one week) were retrospectively evaluated. Tumor- and treatment-associated variables were evaluated in
respect to local control and survival.
Results: Forty-four cats met the inclusion criteria for this study. All cats showed complete response to therapy. Median
disease-free interval (DFI) for all cases was 916 days (95% CI: 456-1377). One- and two-year DFIs were 71% (95%
CI: 56-86%) and 60% (95% CI: 43-77%). Of the tested variables, only tumor volume showed a tendency to
influence DFI, with larger tumors having a 5.4 times greater risk of recurrence than the smaller ones (HR 1.33
(95% CI: 0.99-1.79), p = 0.054). Median overall survival (OS) was 902 days (95% CI: 862-942). One- and 2-year OSs
were 79.3% (95% CI: 67.3-91.3) and 58.4% (95% CI: 42.8-74). Of the tested variables, again, only tumor volume
influenced OS with larger tumors having a 6.3 times greater risk of dying than the smaller ones (HR 1.36
(95% CI: 1.07-1.73), p = 0.010). The acute and late toxicity profile was low and hence clinically acceptable.
Conclusions: Curative-intent radiation therapy with an accelerated fractionation schedule can be considered a
safe, cosmetically superior treatment option for cutaneous squamous cell carcinomas of the nasal planum in cats,
resulting in long and stable tumor control.
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Background
Cutaneous squamous cell carcinoma (cSCC) of the nasal
planum in cats is a common indication for antitumor treat-
ment, and larger, invasive carcinomas are often treated
with external beam radiation therapy. [1–4] These tumors
are mostly caused by chronic exposure to sunlight (ultra-
violet (UV) light) with older and particularly fair-haired
cats being at higher risk. [5] As fur is a physical barrier to
solar-induced lesions, the nasal planum as a non-haired
and often unpigmented area represents a predilection site
for cSCC. The treatment of advanced-stage lesions at this
location can be challenging. [6] Precancerous (actinic)
lesions can persist over months to years, and in some cats
a transformation to a more malignant carcinoma in-situ
and subsequent invasive variant takes place. [7] Progres-
sion is often initially slow, and the pre-malignant or super-
ficial variants of neoplastic condition can be treated by
several means, such as photodynamic therapy [8–10],
strontium-90 plesiotherapy [11, 12], intralesional chemo-
therapy [13], curettage and diathermy. [14] However, for
larger or more invasive tumors, extensive surgical removal
is often a limited treatment option, due to the aesthetically
disfiguring cosmetic outcome. [6, 15] Curative-intent radi-
ation therapy has been described as a cosmetically superior
option for this often rapidly destructive, painful and disfig-
uring variant of the disease, resulting in long and stable
tumor control in these patients. [2–4].
The invasive form of the disease is thought to be a rap-
idly dividing tumor. [2, 3, 16] In prior publications of our
group, an accelerated external beam radiation therapy
protocol applied to a small group of cats with nasal planum
and periocular squamous cell carcinomas was observed to
lead to better responses in cases with high Ki67 reactivity,
i.e. faster proliferating. [2, 3, 16] With these earlier findings
in mind, this retrospective, bi-institutional case series was
compiled to assess the effectiveness of the previously pub-
lished 10 × 4.8 Gy accelerated radiation therapy protocol
in a larger group of cats with macroscopic cSCC of the
nasal planum, and to evaluate tumor and treatment
variables associated with local control and survival. Our
hypothesis was that the accelerated hypofractionated radi-
ation therapy protocol would result in a clinically accept-
able acute and late toxicity profile and provide a long
disease free interval (DFI) and overall survival (OS).
Methods
Study design
Uncontrolled, single-arm retrospective clinical study.
Patient and tumor characteristics
Medical records of cats with squamous cell carcinoma of
the nasal planum admitted to the Division of Radiation
Oncology of the Vetsuisse-Faculty, University of Zurich,
and the Centro Oncologico Veterinario, Sasso Marconi,
Bologna, between 2003 and 2015 were reviewed.
Cats were included in the study if they had a histo-
pathologically or cytologically confirmed diagnosis of
cSCC of the nasal planum and underwent 10 × 4.8 Gy
radiation therapy protocol in a macroscopic setting. The
outcomes of patients with cSCC of the nasal planum
reported in a previous study by our group (n = 12) were
reassessed over a longer follow-up period and included
as well. [3] Adequate available follow-up consisting of
tumor response, date of recurrence or systemic progres-
sion as well as date and cause of death was required.
Clinical staging for regional and distant disease con-
sisted of physical examination, routine complete blood
count and serum biochemistry, fine-needle aspiration of
enlarged regional lymph nodes and thoracic radio-
graphs. Stage was divided into groups with a modified
TNM staging system: T1 was comprised of lesions
measuring <1.5 cm in diameter, T2 consisted of neo-
plasms >1.5 cm in diameter; substage a: non-invasive,
substage b: invasive (each based on histopathology or
visual assessment). [17] Medical records were care-
fully studied in order to retrieve further information
such as: signalment (age, sex, breed), concurrent diseases,
presentation (primary versus recurrent), number of previ-
ous treatments, involved site, tumor size, histology, clin-
ical stage, response to radiation therapy, time to disease
progression, treatment-related side effects or complica-
tions, time and cause of death, and date of last follow-up
visit. In addition, Ki67 levels were evaluated for prognostic
influence. Pathologic diagnoses and grading were made by
an experienced pathologist (FG) as described previ-
ously. [3, 18] In brief, three grades (I, II, and III) were
distinguished, with more malignant morphology indi-
cated by higher grades. The following characteristics
were scored based on a scale: lack of differentiation and
of keratinization, mitotic rate, and nuclear polymorphism.
A proliferation score was determined by means of immu-
nohistochemistry for Ki67 (MIB-1 antigen) as previously
described. [3] In brief, digital images from several ran-
domly chosen regions of each tumor were reviewed and
600–800 cells were counted, each. The percentage of posi-
tive cells was determined and resulted in the following
scores: Score 0 was defined as 0–4% positive cells, score 1
as 5–19%, score 2 as 20–59%, and score 3 as more than
60% positive cells. Tumor size before radiation therapy
was evaluated by caliper measurement during physical
examination. Tumor volume was calculated by the rota-
tional ellipse method (length x width x depth x π/6).
Treatment
All cats were treated with external beam megavoltage radi-
ation therapy. Radiation was delivered with a 6 MV (MV)
linear accelerator (Dynaray LA20; ABB, Clinac DMX or
Gasymova et al. BMC Veterinary Research  (2017) 13:86 Page 2 of 8
Clinac iX, Varian, Palo Alto, USA) using electrons. Positive
lymph nodes were either surgically removed later (n = 1) or
irradiated in a second field (n = 1). Treatment planning was
performed by hand calculation, performed or checked by
the same radiation oncologist at both institutions (CRB).
For the treatments, some of the cats were positioned into a
custom-made bite block for reproducible immobilization.
[19] The GTV (gross tumor volume) was defined as the
macroscopically visible part of the lesion and a CTV (clin-
ical target volume), accounting for subclinical microscopic
disease extension of 5 mm (presumed local infiltration).
The CTV-margin was then extended three-dimensionally
by approximately 1 cm to define the planning target
volume (PTV), accounting for patient motion, and setup
uncertainties. The closest available electron insert (4 × 4 or
6 × 6 cm) was used (diagonally, e.g. the long axis of the field
in line with the cranial-caudal axis of the patient).
The recommendations for specifying dose and vol-
umes were adhered to as proposed in the relevant veter-
inary medical literature. [20, 21] The according fields
(field size of 4×4cm or 6×6cm) were applied at 100 cm
source surface distance (SSD) and energies were chosen
to adequately cover the PTV. Bolus was used to ensure
dose homogeneity and sufficient dose-build up at the
surface. The 90% isodose line was chosen to encompass
this target volume and for dose normalization. [22] The
prescribed dose was 48 Gy delivered in 10 fractions of
4.8 Gy applied twice per day with an interval of 6 h or
more (allowing for normal tissue repair), resulting in an
overall treatment time of 5 consecutive days.
Toxicity
The Veterinary Radiation Therapy Oncology Group
(VRTOG) scheme was used for radiation related tox-
icity assessment at each treatment and 2-3 weeks after
treatment. As further follow-up, monthly rechecks were
recommended. [23] Specific attention was paid to
wound-healing complications in the acute setting, as
well as vascular or osseous complications and second
malignancies in the late setting.
Outcome and follow-up
Outcome information was obtained by the study of med-
ical records or regular phone communication with refer-
ring veterinarians and owners at the end of the study
period. Follow-up care included a medical history and
physical examination at progressive intervals beyond
treatment. Response data was noted in a modified ver-
sion in adherence to response evaluation criteria in solid
tumors (RECIST) guidelines for dogs. [24] Complete
remission (CR) was defined as the disappearance of the
target lesion. Partial response (PR) was defined as a
reduction of at least 30% in the sum of diameters of
target lesions from baseline. Stable disease (SD) was
defined as <30% decrease or <20% increase in the sum of
diameters of target lesions from the smallest sum while on
treatment. Progressive disease (PD) was defined as an in-
crease in the sum of diameters of target lesions by at least
20% over the size present at entry on study, the appear-
ance of new lesions, such as metastatic regional lymph
nodes or distant, pulmonary metastases. Responses were
required to last for at least one month. Follow-up imaging
was based on individual risk or concurrent problems,
eventual symptoms, and/or clinicians’ and/or owners’
preferences, and included thoracic radiographs and
abdominal ultrasound.
Statistical analysis
Statistical evaluation was performed under the supervi-
sion of a biostatistician (M.R.) and computed with a
commercial statistical software package (IBM® SPSS®
Statistics, Version 23). Description of quantitative data
characteristics, other than disease-free interval (DFI) and
overall survival (OS), is given by mean (± SD), unless
otherwise specified. Description of qualitative character-
istics is provided in absolute and relative frequencies.
DFI was defined as the interval between the last day of
radiation therapy to measurable progression of disease.
OS was defined as the interval between the first fraction
of radiation therapy and death. Cats that were still free of
progression at the time of data evaluation were censored
for DFI analyses. For OS, all deaths were considered
events and cats that were still alive at the time of data
evaluation or lost to follow-up were censored. Kaplan-
Meier survival analysis was used and followed by Logrank
or Breslow-Gehan-Wilcoxon tests. In the absence of
crossing of survival curves, the Logrank test was applied.
Otherwise the Breslow-Gehan-Wilcoxon test was used.
The univariate and multiple Cox-regression analysis was
used to determine whether the following factors were
significantly associated with DFI or OS: age, weight, sex,
histological grade (I versus II versus III), tumor size,
tumor stage (and substage), Ki67 proliferation index, as
well as the pre-treatment hematologic parameters
(hemoglobin (Hb) and packed cell volume (PCV)). Distri-
bution in tumor volumes were skewed; thus logarithmic-
ally transformed values were used rather than raw
measurements (lnVol). Survival estimates are presented as
median with the corresponding 95% confidence intervals
(95% CI). Moreover, Hazard-Ratio (HR) together with the
corresponding 95% CI is reported. Results of statistical
analyses with p-value less than 0.05 were interpreted as
statistically significant.
Results
Patient and tumor characteristics
Forty-four cats met the inclusion criteria for this study.
Twenty-one of the cats were female (19 spayed) and 23
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were male (22 neutered). The cats were mostly domestic
short-hair (n = 41), 2 were of Angora breed and 1 Turkish
van. The ages ranged from 5 to 16 years with a mean of
11.3 (± 2.7) years. Body weight ranged from 2.9–7.4 kg,
with a mean of 4.7 (± 1.1) kg. Thirty-four animals were
treated at the Division of Radiation Oncology of the
Vetsuisse-Faculty, University of Zurich, Switzerland and
10 animals at the Centro Oncologico Veterinario, Sasso
Marconi, Bologna, Italy.
One cat had two prior surgical tumor removals.
Packed cell volume ranged from 19 to 49.7% with a
mean of 34.0% (± 7.3), (n = 44). Hemoglobin ranged
from 5.9-15.2 g/dl, with a mean of 11.0 g/dl (± 2.4),
(n = 43). Pretreatment tumor volumes were 0.2 to
70.6 mm3, with a mean of 15.0 mm3 (± 19.1), and trans-
formed volumes (lnVol) -1.7 to 4.3, with a mean of 1.6
(± 1.7). Regarding stage, 18.2% (n = 8) were stage T1a,
38.6% (n = 17) T1b, 4.5% (n = 2) T2a and 38.6% (n = 17)
T2b tumors. Diagnosis of cSCC was histologically con-
firmed in 84% (n = 37) and cytologically in 16% (n = 7).
Of the 44 cases, two had cytologically confirmed positive
lymph nodes (4.5%) at the time of tumor diagnosis, none
of the cats presented with distant metastasis. Of these
two cats, one had lymph node excision two months after
radiation therapy, in the other cat, the lymphnode was
irradiated in a second treatment field. It was possible to
assign histological grade in 54.5% of the cases (n = 24).
Of these tumors, 20.8% were of grade 1 (n = 5), 50% of
grade 2 (n = 12), and 29.2% of grade 3 (n = 7). For the
remaining 20 cases, the histological samples were not
retrievable; hence grade could not be assessed. Ki67
positivity could be evaluated in 23 cats and ranged from
36.7-81.6% with a mean of 53.2% (±13.6). When de-
scribed as a score, 15 cats had a Ki67 score 2 and 8 cats
a score 3 (Table 1).th=tlb=
Treatment protocol, side effects
All cats were treated with single electron fields with
energies ranging from 6 to 9 MeV, 6 MeV was used in
40 cats (90.1%) and 9 MeV in 4 cats (9%). Acute side
effects were assessed in 39 cases and consisted of grade
0 toxicity in 3 cats (7.7%), grade 1 toxicity (erythema,
dry desquamation, alopecia or epilation) in 23 cats
(59%), grade 2 toxicity (patchy, moist desquamation,
without edema) in 11 cats (28.2%), and grade 3 toxicity
(confluent moist desquamation with edema and/or
ulceration) in two cats (5.1%). Late effects were assessed
in 39 cases with no toxicity in 13 cats (34.2%), grade 1
toxicity (alopecia, leukotrichia) in 22 cats (57.9%), and
grade 3 toxicity (necrosis, panophthalmitis, blindness) in
3 cats (7.9%). Each of these 3 cats showed different late
effects, which manifested as maxillary bone necrosis,
chronic moderate stomatitis and glaucoma secondary to
panophthalmitis (uveitis) (the latter developed in a
patient with a small tumor, without prior acute reactions
in this eye and with no known association to a large
treatment field) in one cat, each.
Response to treatment
Median follow-up time for censored cases (n = 12, still
alive or lost to follow-up) was 659 days (range 350–
1894 days). Of the 12 censored cases 7 cats were still alive
at the time of analysis (range 350–1894 days), and 5 were
lost to follow-up (range 360-917 days). Of the 32 animals
that were known to have died, 19 (65.6%) died of tumor-
related or unknown (n = 2) reasons and 11 (34.4%) died of
tumor-unrelated causes. At the first evaluation at 2-
3 weeks after finishing radiation therapy, response evalu-
ation was performed in all cats. All tumors (100%) had a
complete local response (with one cat having the un-
treated lymphnode removed after 8 weeks of RT). Median
disease free interval for all cases was 916 days (95% CI:
456–1377) (30.1 months). One- and 2-year DFIs were 71%
(95% CI: 56–86) and 60% (95% CI: 43–77), Fig. 1. No dif-
ference was seen in DFI between the patients treated at
the different institutions (p = 0.249). Of the tested
variables, only tumor volume (lnVol) showed the highest
tendency to influence DFI, with larger tumors having a
5.4-times greater risk of recurrence than the smaller ones
(HR 1.33 (95% CI: 0.99–1.79), p = 0.054).
Median overall survival was 902 days (95% CI: 862–942)
(29.6 months). One- and 2-year OSs were 79.3% (95% CI:
67.3–91.3) and 58.4% (95% CI: 42.8–74), Fig. 2. Between
the patients treated at the different institutions, no differ-
ence was seen in OS (p = 0.293). Of the tested variables,
again, only tumor volume (lnVol) influenced OS with
larger tumors having an 6.3-times greater risk of dying
than the smaller ones (HR 1.36 (95% CI: 1.07–1.73),
p = 0.010). Eight of the patients (18.1%) received an
additional treatment at the time of tumor progression,
consisting of photodynamic therapy (n = 5) or prednisone
(n = 3). This additional treatment prolonged survival for a
mean of 137 days (range 15-264; 95% CI: 64–210 days).
On multiple Cox-regression analysis, no further
associations other than of tumor volume were found
to influence DFI or OS.
Discussion
Prior work has documented the effectiveness of ionizing
radiation for treatment of feline nasal cSCC, resulting in
partial or complete response in 93–100% and reported
median progression free times of 16.5 (±3.6) months,
(mean 27.6 (±3.4)) [4] with 1-year disease free survivals
of 60.1% (±5.5%) [4], and estimated 1-year disease free
survivals of 64% [2] and about 58% [3]. Similar to the
present study, these numbers were determined in a retro-
spective manner, with various differences regarding radio-
therapy techniques and protocols; hence a comparative
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Table 1 Overview of all treated cats included in the study
Nr Age [years] Weight [kg] PCV [%] Hb [g/dl] TNM Grade Ki 67 [% positive cells] Ki 67 [score] DFI [days] OS [days]
1a 11.0 3.3 36.0 T2bN1M0 3 60.6 3 1′432 1′436
2a 8.0 3.3 42.0 12.7 T1bN0M0 2 36.7 2 365 1′227
3a 11.0 4.9 24.0 8.6 T2bN0M0 2 58.7 2 916 1′017
4a 12.0 5.7 34.0 8.6 T1aN0M0 2 50.2 2 456b 460
5a 12.0 3.0 27.0 9.1 T2bN0M0 2 45.3 2 913b 917b
6a 8.5 6.3 35.0 10.2 T1bN0M0 2 63.8 3 2′173b 2′177
7a 8.0 4.7 42.0 14.2 T1aN0M0 2 42.7 2 87 124
8a 14.0 3.1 21.0 7.0 T2bN0M0 1 46.3 2 139 198
9a 8.7 5.1 24.0 8.2 T1aN0M0 1 74.9 3 2′155 2′423
10a 9.5 4.0 29.0 11.6 T2aN0M0 3 81.6 3 656 900
11 12.0 6.9 27.0 8.9 T1bN0M0 2 43.9 2 530b 534
12a 15.0 4.6 27.0 8.6 T1bN0M0 3 71 3 1′721b 1′725
13a 4.0 34.0 11.6 T2bN0M0 2 52.7 2 266b 270
14 11.0 4.3 23.0 8.3 T2bN0M0 1 69.5 3 67 74
15 13.0 5.1 39.0 11.8 T1aN0M0 2 51.8 2 538b 542b
16 14.0 3.7 36.0 12.7 T1aN0M0 177 874
17 15.0 7.4 33.0 10.9 T1bN0M0 3 41.4 2 858 902
18 11.0 3.6 44.0 15.2 T2bN0M0 3 61.4 3 271 277
19 9.0 4.9 33.0 10.5 T2bN0M0 1 40.4 2 208 362
20 12.0 4.0 31.0 11.0 T2bN0M0 363 367
21 7.0 4.1 44.0 15.0 T2bN0M0 351 1′514
22 15.0 3.8 30.0 10.5 T1bN0M0 2 71.8 3 726b 730b
23 11.0 4.2 26.0 8.7 T1bN0M0 3 38.1 2 956b 960b
24 11.0 5.6 32.6 6.0 T2bN1M0 2 42.2 2 358 472
25 15.0 4.3 19.0 5.9 T2bNxM0 3 38.5 2 339 490
26 14.0 5.0 36.0 12.4 T2bN0M0 641 659
27 10.0 3.9 30.0 10.0 T1bNxM0 1 482b 486b
28 11.0 3.9 32.0 11.1 T1bN0M0 473 570
29 14.0 3.4 26.0 8.7 T2bN0M0 1′460b 1′464
30 13.0 4.9 39.0 13.3 T2bN0M0 226 230
31 8.0 4.0 36.0 12.8 T2bN0M0 466b 470
32 13.0 5.0 44.2 14.8 T1aN0M0 356b 360b
33 11.2 6.1 43.0 14.1 T1aN0M0 808b 812b
34 16.0 2.9 45.3 13.6 T2bN0M0 346b 350b
35 14.0 7.3 45.1 14.1 T2bN0M0 184b 189
36 14.0 4.2 29.3 9.6 T2bN0M0 17b 22
37 11.0 3.7 49.7 14.9 T1aN0M0 1′078 1′082
38 9.0 5.6 34.6 10.1 T2bN0M0 153 195
39 9.0 6.2 37.0 13.0 T2bN0M0 1′890b 1′894b
40 14.0 4.7 41.9 13.1 T1bN0M0 452b 452b
41 8.0 4.6 36.0 10.9 T1bN0M0 2 40.9 2 728b 732b
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interpretation of outcomes must be undertaken with care.
The accelerated protocol reported here resulted in a
fast and complete resolution of disease in all de-
scribed cats. While the patients experiencing complete
remission are not reported in one study [4], proton
irradiation led to a complete remission in only 60% of
the cases. [2] While the median DFI of 30.1 months
(95% CI: 15–45.2 months) in this study is longer than
previously reported [4], the 1- and 2-year DFIs of 71%
(95% CI: 56–86) and 60% (95% CI: 43–77) are comparable
with other studies, as their 1- and 2-year DFIs lie within
our 95%CI range. Also, the overall survival with a median
of 29.6 months in this study (95% CI: 28.3–30.9 months)
and the 1- and 2-year survival of 79.3% (95% CI: 67.3–
91.3 and 58.4% (95% CI: 42.8–74), respectively, are com-
parable to reported findings [2]. Overall survival has to be
interpreted with care, as it is not an ideal readout of treat-
ment efficacy in this disease. The patients of our cohort
that received additional treatments upon recurrence lived
a median 4.5 months longer.
Comparable to as described in other publications,
radiation treatment was well tolerated by most of the
patients in this study, with clinically acceptable acute
and few long-term effects. [2–4] However, due to the
retrospective nature of the study, some of the mild late
toxicities such as alopecia could have been underreported.
Only two cats had acute toxicity of grade 3 and they were
of short duration. Three cats (7.7%) had suspected grade 3
late toxicity, which manifested in maxillary bone necrosis,
chronic moderate stomatitis and glaucoma, in one case
each. These side effects were rated to their highest degree
and readily attributed to radiation therapy, despite the
possibility of other underlying causes, such as for instance
chronic infections due to dental disease or viral causes.
However, it is expected that the accelerated delivery of
dose leads to more severe acute side effects and the high
dose per fraction and the higher incidence of acute
effects can increase the risk of (consequential) late
toxicity. [25, 26] It has to be taken into consideration
that the onset of late toxicity has a time dependency
and that the development of late adverse effects
observed in our study will correspond better to the true
incidence (compared to earlier studies) due to the
longer follow-up period in this group of cats.
Compared to the outcome of the previous work of our
group [2] the DFI in this study was significantly longer
Fig. 1 Disease free interval. The vertical dashed lines indicate 1
and 2 years Fig. 2 Overall survival. The vertical dashed lines indicate 1 and 2 years
Table 1 Overview of all treated cats included in the study (Continued)
42 6.0 5.5 30.7 10.8 T2bN0M0 347b 351b
43 5.0 5.0 32.5 10.3 T1bN0M0 902b 906
44 12.0 6.1 37.0 9.9 T2aN0M0 487b 492
PCV Packed cell volume, Hb Hemoglobin, TNM Modified staging system, x Missing data, DFI Disease free interval, OS Overall survival, acats previously reported [3],
with a longer follow-up; bAll deaths were considered events; cats still free of progression, alive at the time of data evaluation or lost to
follow-up were censored
Gasymova et al. BMC Veterinary Research  (2017) 13:86 Page 6 of 8
due to longer follow up time, as most of the original cats
could be followed until death.
Data from the present study did not support previous
observations indicating that higher proliferation rates
(determined either with Ki67 or with PCNA immunohis-
tochemistry) might be associated with longer DFIs. [3, 4]
Since these two prior studies used two different methods
(Ki67 vs. PCNA) an exact comparison cannot be made.
Possibly due to the small number of cases the prolifera-
tive fraction assessed with Ki67 in our study had no
prognostic significance. Or the prognostic significance of
Ki67 truly does not exist. In contrast, tumor volume was
found to be associated with shorter relapse-free periods
and remains the only prognostic factor in our findings.
[4] However Ki67 proliferation rate in this study was
high for most of the cases and ranged from 36.7-81.6%,
which suggests the aggressive nature of the tumors and
can still justify the accelerated treatment approach.
Due to the use of archival data and considering the
difficulty of exact clinical assessment of late toxicities,
the authors may not have been able to describe the full
range of responses in these cats. In addition, information
gathered by telephone follow-up could have possibly
skewed the described results by owner’s perception. DFIs
might have been overstated as many of the animals were
seen on progression and the exact onset of disease pro-
gression might have been observed incorrectly by the
owner. The bi-institutionality of the study is of a lesser
concern, as the treatment planning (e.g. the electron
hand calculations) was done under the direct supervi-
sion of one radiation oncologist (CRB). Further limita-
tions were that the grading was not available for every
patient and that some biopsy specimens available were
small-sized.
Conclusions
Curative-intent radiation therapy with an accelerated
fractionation schedule can be considered a safe, cosmet-
ically superior treatment option for invasive cSCC of the
nasal planum in cats. Considering that this treatment
regime results in long and stable tumor control and can
be conveniently delivered in a one-week period, it can
be further recommended as current standard treatment.
Abbreviations
CR: Complete remission; cSCC: Cutaneous squamous cell carcinoma;
CTV: Clinical target volume; DFI: Disease-free interval; GTV: Gross tumor
volume; Gy: Gray; Hb: Hemoglobin; MeV: Mega electron volt; MV: Megavolt;
OS: Overall survival; PCV: Packed cell volume; PD: Progressive disease;
PR: Partial response; PTV: Planning target volume; RT: Radiation therapy;
SD: Stable disease; SSD: Source surface distance; TNM: Tumor – Node –
(distant) Metastasis; UV: Ultraviolet
Acknowledgements
Not applicable.
Funding
None.
Availability of data and materials
Not applicable. The dataset analyzed during the current study is available
from the corresponding author on request.
Authors’ contributions
EG and CRB conceived the study and participated in its design and
coordination. EG, MR, VM and CRB wrote the final version of the manuscript.
EG, SC and FG collected and evaluated the clinical and pathological data. EG
and CRB performed statistical analysis verified by MR and interpreted the
data obtained. All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable. No formal ethics approval from the Animal Ethics Council of
the Canton of Zurich, Switzerland was needed for this already published
protocol.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Radiation Oncology, Vetsuisse-Faculty, University of Zurich,
CH-8057 Zurich, Switzerland. 2Institute of Veterinary Pathology, Vetsuisse
Faculty, University of Zurich, CH-8057 Zurich, Switzerland. 3Centro
Oncologico Veterinario, 40037 Sasso Marconi (BO), Italy. 4Department of
Biostatistics, Epidemiology Biostatistics and Prevention Institute, Faculty of
Medicine, University of Zurich, CH-8001 Zurich, Switzerland.
Received: 19 December 2016 Accepted: 1 April 2017
References
1. Cunha SC, Carvalho LA, Canary PC, Reisner M, Corgozinho KB, Souza HJ,
Ferreira AM. Radiation therapy for feline cutaneous squamous cell
carcinoma using a hypofractionated protocol. J Feline Med Surg.
2010;12(4):306–13.
2. Fidel JL, Egger E, Blattmann H, Oberhansli F, Kaser-Hotz B. Proton irradiation
of feline nasal planum squamous cell carcinomas using an accelerated
protocol. Vet Radiol Ultrasound. 2001;42(6):569–75.
3. Melzer K, Guscetti F, Rohrer Bley C, Sumova A, Roos M, Kaser-Hotz B. Ki67
reactivity in nasal and periocular squamous cell carcinomas in cats treated
with electron beam radiation therapy. J Vet Intern Med. 2006;20(3):676–81.
4. Theon AP, Madewell BR, Shearn VI, Moulton JE. Prognostic factors
associated with radiotherapy of squamous cell carcinoma of the nasal plane
in cats. J Am Vet Med Assoc. 1995;206(7):991–6.
5. Miller MA, Nelson SL, Turk JR, Pace LW, Brown TP, Shaw DP, Fischer JR,
Gosser HS. Cutaneous neoplasia in 340 cats. Vet Pathol. 1991;28(5):389–95.
6. Murphy S. Cutaneous squamous cell carcinoma in the cat: current
understanding and treatment approaches. J Feline Med Surg. 2013;15(5):401–7.
7. Hauck ML: Tumors of the skin and subcutaneous tissues. In: Small Animal
Clinical Oncology. 5th edn. Edited by Withrow V, Page. St. Louis, MI: Elsevier
Saunders; 2013: 305-320.
8. Bexfield NH, Stell AJ, Gear RN, Dobson JM. Photodynamic therapy of
superficial nasal planum squamous cell carcinomas in cats: 55 cases. J Vet
Intern Med. 2008;22(6):1385–9.
9. Buchholz J, Wergin M, Walt H, Grafe S, Bley CR, Kaser-Hotz B. Photodynamic
therapy of feline cutaneous squamous cell carcinoma using a newly
developed liposomal photosensitizer: preliminary results concerning drug
safety and efficacy. J Vet Intern Med. 2007;21(4):770–5.
10. Stell AJ, Dobson JM, Langmack K. Photodynamic therapy of feline superficial
squamous cell carcinoma using topical 5-aminolaevulinic acid. J Small Anim
Pract. 2001;42(4):164–9.
Gasymova et al. BMC Veterinary Research  (2017) 13:86 Page 7 of 8
11. Goodfellow M, Hayes A, Murphy S, Brearley M. A retrospective study of
(90)strontium plesiotherapy for feline squamous cell carcinoma of the nasal
planum. J Feline Med Surg. 2006;8(3):169–76.
12. Hammond GM, Gordon IK, Theon AP, Kent MS. Evaluation of strontium Sr 90
for the treatment of superficial squamous cell carcinoma of the nasal planum
in cats: 49 cases (1990-2006). J Am Vet Med Assoc. 2007;231(5):736–41.
13. Theon AP, VanVechten MK, Madewell BR. Intratumoral administration of
carboplatin for treatment of squamous cell carcinomas of the nasal plane in
cats. Am J Vet Res. 1996;57(2):205–10.
14. Jarrett RH, Norman EJ, Gibson IR, Jarrett P. Curettage and diathermy: a
treatment for feline nasal planum actinic dysplasia and superficial squamous
cell carcinoma. J Small Anim Pract. 2013;54(2):92–8.
15. Thomson M. Squamous cell carcinoma of the nasal planum in cats and
dogs. Clin Tech Small Anim Pract. 2007;22(2):42–5.
16. Schwyn U, Crompton NE, Blattmann H, Hauser B, Klink B, Parvis A, Ruslander
D, Kaser-Hotz B. Potential tumour doubling time: determination of Tpot for
various canine and feline tumours. Vet Res Commun. 1998;22(4):233–47.
17. Magne ML, Rodriguez CO, Autry SA, Edwards BF, Theon AP, Madewell BR.
Photodynamic therapy of facial squamous cell carcinoma in cats using a
new photosensitizer. Lasers Surg Med. 1997;20(2):202–9.
18. Carpenter LG, Withrow SJ, Powers BE, Ogilvie GK, Schwarz PD, Straw RC,
LaRue SM, Berg J. Squamous cell carcinoma of the tongue in 10 dogs. J Am
Anim Hosp Assoc. 1993;29:17–24.
19. Rohrer Bley C, Blattmann H, Roos M, Sumova A, Kaser-Hotz B. Assessment of
a radiotherapy patient immobilization device using single plane port
radiographs and a remote computed tomography scanner. Vet Radiol
Ultrasound. 2003;44(4):470–5.
20. Keyerleber MA, McEntee MC, Farrelly J, Podgorsak M. Completeness of reporting
of radiation therapy planning, dose, and delivery in veterinary radiation oncology
manuscripts from 2005 to 2010. Vet Radiol Ultrasound. 2012;53(2):221–30.
21. International Commission of Radiation Units and Measurements. Prescribing,
recording and reporting electron beam therapy, ICRU Report 71, J ICRU Vol.
4(1). Oxford: Oxford University Press; 2004.
22. Das IJ, Cheng CW, Healey GA. Optimum field size and choice of isodose lines
in electron beam treatment. Int J Radiat Oncol Biol Phys. 1995;31(1):157–63.
23. Ladue T, Klein MK. Toxicity criteria of the veterinary radiation therapy
oncology group. Vet Radiol Ultrasound. 2001;42(5):475–6.
24. Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria
for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group
(VCOG) consensus document. Vet Comp Oncol. 2015;13(3):176–83.
25. Dorr W, Hendry JH. Consequential late effects in normal tissues. Radiother
Oncol. 2001;61(3):223–31.
26. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A
randomised multicentre trial of CHART versus conventional radiotherapy in
head and neck cancer. Radiother Oncol. 1997;44(2):123–36.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gasymova et al. BMC Veterinary Research  (2017) 13:86 Page 8 of 8
